Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-C-methylcytidine is a synthetic nucleoside analog with broad-spectrum antiviral activity, primarily investigated for its effects against hepatitis C virus (HCV), norovirus, and dengue virus. After cellular uptake, it is phosphorylated to its active triphosphate form, which acts as a chain terminator by inhibiting viral RNA-dependent RNA polymerase (notably the HCV NS5B polymerase). This inhibition blocks viral RNA synthesis and replication. It was the first nucleoside inhibitor of HCV NS5B polymerase shown to reduce viral load in patients with HCV infection. The compound has also demonstrated efficacy in preclinical models against norovirus and dengue virus[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-C-methylcytidine.